Overview
Typhoid colitis, primarily caused by Salmonella enterica serovar Typhi, is an invasive gastrointestinal infection characterized by inflammation of the colon. This condition is clinically significant due to its potential for severe systemic complications if untreated, including typhoid fever with high fever, systemic toxicity, and gastrointestinal symptoms such as diarrhea and abdominal pain. It predominantly affects individuals in areas with poor sanitation and limited access to clean water, impacting predominantly children and young adults. Early recognition and appropriate management are crucial in day-to-day practice to prevent complications and reduce mortality rates 4.Pathophysiology
The pathophysiology of typhoid colitis involves the invasion of Salmonella Typhi into the intestinal mucosa, primarily through the Peyer's patches of the small intestine. Once inside, these bacteria multiply and spread to mesenteric lymph nodes, spleen, and liver, leading to systemic dissemination. The host immune response, particularly the production of pro-inflammatory cytokines such as TNF-α and IL-1β, contributes significantly to the inflammatory cascade observed in the colon. This inflammatory response manifests as colitis, characterized by mucosal ulceration, edema, and infiltration of neutrophils and macrophages. The interplay between bacterial virulence factors and host inflammatory mediators drives the clinical manifestations, highlighting the importance of anti-inflammatory strategies in management 34.Epidemiology
Typhoid colitis has a notable global burden, particularly in developing countries with suboptimal sanitation and hygiene practices. Incidence rates vary widely, with estimates ranging from 10 to 300 cases per 100,000 population annually in endemic regions. Children and young adults are most frequently affected, with a slight male predominance observed in some studies. Geographic risk factors include areas with poor water treatment and sanitation infrastructure. Trends over time show a decline in incidence in regions with improved public health measures but persistent challenges in endemic areas. Travel to and from these regions also contributes to sporadic cases in non-endemic areas 4.Clinical Presentation
The clinical presentation of typhoid colitis typically includes a gradual onset of symptoms over one to three weeks post-exposure. Common features include sustained high fever, headache, malaise, anorexia, and a characteristic rash known as "rose spots." Gastrointestinal symptoms such as mild to severe diarrhea, abdominal pain, and sometimes constipation, are hallmark signs of colitis involvement. Atypical presentations can include hepatosplenomegaly and neurological symptoms like confusion or delirium. Red-flag features include significant dehydration, persistent high fever unresponsive to antibiotics, and signs of sepsis, which necessitate urgent evaluation and intervention 4.Diagnosis
Diagnosing typhoid colitis involves a combination of clinical assessment and laboratory investigations. The diagnostic approach typically starts with a thorough history and physical examination focusing on travel history, exposure risks, and symptomatology. Key diagnostic criteria include:Management
The management of typhoid colitis follows a stepwise approach aimed at reducing morbidity and mortality:First-Line Treatment
Second-Line Treatment
Refractory or Complicated Cases
Complications
Common complications of typhoid colitis include:Prognosis & Follow-Up
The prognosis for typhoid colitis is generally good with prompt and appropriate antibiotic therapy, with recovery typically within weeks. Prognostic indicators include early diagnosis, absence of complications, and adherence to treatment. Follow-up should include:Special Populations
Key Recommendations
References
1 Holanda BF, Freitas de Araujo D, da Silva JNR, Pereira MG, de Freitas Pires A, Assreuy AM. Polysaccaride-rich extract of Caesalpina ferrea stem barks attenuates mice acute inflammation induced by zymosan: Oxidative stress modulation. Journal of ethnopharmacology 2021. link 2 Silva LR, Alves AF, Cavalcante-Silva LHA, Braga RM, de Almeida RN, Barbosa-Filho JM et al.. Milonine, a Morphinandienone Alkaloid, Has Anti-Inflammatory and Analgesic Effects by Inhibiting TNF-α and IL-1β Production. Inflammation 2017. link 3 Gayathri B, Manjula N, Vinaykumar KS, Lakshmi BS, Balakrishnan A. Pure compound from Boswellia serrata extract exhibits anti-inflammatory property in human PBMCs and mouse macrophages through inhibition of TNFalpha, IL-1beta, NO and MAP kinases. International immunopharmacology 2007. link 4 Feng P, Rahim RT, Cowan A, Liu-Chen LY, Peng X, Gaughan J et al.. Effects of mu, kappa or delta opioids administered by pellet or pump on oral Salmonella infection and gastrointestinal transit. European journal of pharmacology 2006. link